MetaVia (MTVA) Competitors $1.60 -0.04 (-2.21%) As of 02/21/2025 03:48 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsSEC FilingsTrends MTVA vs. VNRX, OTLK, RPTX, PDSB, IMMX, PRLD, RNTX, ESLA, CNTB, and LTRNShould you be buying MetaVia stock or one of its competitors? The main competitors of MetaVia include VolitionRx (VNRX), Outlook Therapeutics (OTLK), Repare Therapeutics (RPTX), PDS Biotechnology (PDSB), Immix Biopharma (IMMX), Prelude Therapeutics (PRLD), Rein Therapeutics (RNTX), Estrella Immunopharma (ESLA), Connect Biopharma (CNTB), and Lantern Pharma (LTRN). These companies are all part of the "pharmaceutical products" industry. MetaVia vs. VolitionRx Outlook Therapeutics Repare Therapeutics PDS Biotechnology Immix Biopharma Prelude Therapeutics Rein Therapeutics Estrella Immunopharma Connect Biopharma Lantern Pharma VolitionRx (NYSE:VNRX) and MetaVia (NASDAQ:MTVA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, community ranking, earnings, valuation and risk. Which has better earnings and valuation, VNRX or MTVA? MetaVia has lower revenue, but higher earnings than VolitionRx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVolitionRx$770K66.49-$35.32M-$0.36-1.53MetaViaN/AN/A-$12.47MN/AN/A Is VNRX or MTVA more profitable? MetaVia has a net margin of 0.00% compared to VolitionRx's net margin of -2,321.14%. VolitionRx's return on equity of 0.00% beat MetaVia's return on equity.Company Net Margins Return on Equity Return on Assets VolitionRx-2,321.14% N/A -163.39% MetaVia N/A -189.12%-122.31% Does the MarketBeat Community prefer VNRX or MTVA? VolitionRx received 7 more outperform votes than MetaVia when rated by MarketBeat users. However, 100.00% of users gave MetaVia an outperform vote while only 14.81% of users gave VolitionRx an outperform vote. CompanyUnderperformOutperformVolitionRxOutperform Votes814.81%Underperform Votes4685.19% MetaViaOutperform Votes1100.00% Underperform VotesNo Votes Which has more risk & volatility, VNRX or MTVA? VolitionRx has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, MetaVia has a beta of -0.22, indicating that its stock price is 122% less volatile than the S&P 500. Does the media favor VNRX or MTVA? In the previous week, VolitionRx had 1 more articles in the media than MetaVia. MarketBeat recorded 1 mentions for VolitionRx and 0 mentions for MetaVia. VolitionRx's average media sentiment score of 0.59 beat MetaVia's score of 0.00 indicating that VolitionRx is being referred to more favorably in the media. Company Overall Sentiment VolitionRx Positive MetaVia Neutral Do insiders and institutionals have more ownership in VNRX or MTVA? 8.1% of VolitionRx shares are held by institutional investors. Comparatively, 1.4% of MetaVia shares are held by institutional investors. 12.8% of VolitionRx shares are held by insiders. Comparatively, 1.1% of MetaVia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts rate VNRX or MTVA? VolitionRx currently has a consensus price target of $3.75, suggesting a potential upside of 578.73%. MetaVia has a consensus price target of $12.00, suggesting a potential upside of 648.22%. Given MetaVia's stronger consensus rating and higher possible upside, analysts plainly believe MetaVia is more favorable than VolitionRx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VolitionRx 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67MetaVia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryVolitionRx beats MetaVia on 9 of the 15 factors compared between the two stocks. Get MetaVia News Delivered to You Automatically Sign up to receive the latest news and ratings for MTVA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MTVA vs. The Competition Export to ExcelMetricMetaViaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.82M$7.06B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E RatioN/A5.8226.1519.13Price / SalesN/A268.05435.3370.72Price / CashN/A65.6738.0134.83Price / Book0.476.717.644.62Net Income-$12.47M$138.55M$3.19B$245.94M7 Day Performance-4.19%-2.63%-2.11%-2.62%1 Month Performance-14.69%-2.33%-0.49%-2.15%1 Year PerformanceN/A-5.33%16.44%12.95% MetaVia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MTVAMetaVia1.6263 of 5 stars$1.60-2.2%$12.00+648.2%N/A$13.82MN/A0.0010VNRXVolitionRx1.8893 of 5 stars$0.61-3.8%$3.75+518.8%-43.1%$56.16M$770,000.00-1.6880OTLKOutlook Therapeutics2.0837 of 5 stars$1.71-8.6%$12.00+601.8%-81.3%$54.69MN/A-0.1920Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageRPTXRepare Therapeutics3.005 of 5 stars$1.28+0.8%$7.00+446.9%-79.0%$54.41M$51.13M-0.64180Upcoming EarningsPDSBPDS Biotechnology1.0382 of 5 stars$1.42-9.0%$11.67+721.6%-74.7%$53.12MN/A-1.2220News CoverageGap UpIMMXImmix Biopharma2.6022 of 5 stars$1.93-2.5%$7.00+262.7%-41.1%$53.09MN/A-2.279PRLDPrelude Therapeutics2.2733 of 5 stars$0.95-2.2%$4.00+321.6%-77.0%$52.21MN/A-0.53120Gap UpRNTXRein TherapeuticsN/A$2.35-3.7%N/AN/A$50.92MN/A-0.759Gap DownESLAEstrella Immunopharma2.7907 of 5 stars$1.41+13.8%$16.00+1,038.8%+42.3%$50.83MN/A-5.40N/AAnalyst ForecastNews CoverageGap UpHigh Trading VolumeCNTBConnect Biopharma2.9825 of 5 stars$0.91-1.3%$8.00+778.6%-24.3%$50.31MN/A0.00110LTRNLantern Pharma0.4623 of 5 stars$4.55-9.2%N/A+10.2%$49.05MN/A-2.5620News Coverage Related Companies and Tools Related Companies VNRX Alternatives OTLK Alternatives RPTX Alternatives PDSB Alternatives IMMX Alternatives PRLD Alternatives RNTX Alternatives ESLA Alternatives CNTB Alternatives LTRN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MTVA) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MetaVia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MetaVia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
